These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 23038659

  • 1. Capecitabine-induced hypertriglyceridemia and hyperglycemia: two cases.
    Duman BB, Paydas S, Tetiker T, Gunaldı M, Afsar CU, Erçolak V, Haksöyler V, Dilli MŞ.
    Pharmacology; 2012; 90(3-4):212-5. PubMed ID: 23038659
    [Abstract] [Full Text] [Related]

  • 2. Capecitabine-induced severe hypertriglyceridemia: report of two cases.
    Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N.
    Ann Pharmacother; 2006 Feb; 40(2):328-31. PubMed ID: 16391007
    [Abstract] [Full Text] [Related]

  • 3. Capecitabine-induced hypertriglyceridemia: a report of two cases.
    Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP.
    Anticancer Res; 2006 Feb; 26(3B):2249-51. PubMed ID: 16821596
    [Abstract] [Full Text] [Related]

  • 4. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
    Bar-Sela G, Haim N.
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
    [Abstract] [Full Text] [Related]

  • 5. Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature.
    Han GH, Huang JX.
    J Oncol Pharm Pract; 2015 Oct; 21(5):380-3. PubMed ID: 24781450
    [Abstract] [Full Text] [Related]

  • 6. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
    Seminara P, Losanno T, Emiliani A, Manna G.
    Cardiology; 2010 Oct; 116(1):42-4. PubMed ID: 20431291
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D, Alessandroni P, Catalano V, Giordani P, Fedeli SL, Fedeli A, Baldelli AM, Casadei V, Ceccolini M, Catalano G.
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Jeung HC, Chung HC.
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):141-3. PubMed ID: 20887492
    [No Abstract] [Full Text] [Related]

  • 17. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H.
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [Abstract] [Full Text] [Related]

  • 18. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE, Kim YC.
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [Abstract] [Full Text] [Related]

  • 19. Management of hand-foot syndrome induced by capecitabine.
    Gressett SM, Stanford BL, Hardwicke F.
    J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
    [Abstract] [Full Text] [Related]

  • 20. Increase in triglyceride blood level in patients treated with capecitabine: a retrospective survey.
    Bar-Sela G, Cohensius-Kent D, Vornikova O, Haim N.
    Anticancer Drugs; 2014 Jul; 25(6):729-34. PubMed ID: 24595094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.